These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 11965039

  • 21. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F.
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [Abstract] [Full Text] [Related]

  • 22. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J.
    Clin Transplant; 2008 Dec; 22(2):200-10. PubMed ID: 18339140
    [Abstract] [Full Text] [Related]

  • 23. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM, Gentil-Govantes MÁ, González-Molina M, Rivero M, Cantarell C, Alarcón A, Franco A, Sánchez-Plumed J, Lampreabe I, Lauzurica R, González E, Romero R, Ruiz-San Millán JC, Osuna A.
    Nefrologia; 2012 Jul 17; 32(4):446-54. PubMed ID: 22806279
    [Abstract] [Full Text] [Related]

  • 24. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study.
    N Engl J Med; 2007 Dec 20; 357(25):2562-75. PubMed ID: 18094377
    [Abstract] [Full Text] [Related]

  • 25. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, Kirkman RL, Milford EL.
    J Am Soc Nephrol; 2000 Oct 20; 11(10):1903-1909. PubMed ID: 11004222
    [Abstract] [Full Text] [Related]

  • 26. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Oct 20; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 27. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G.
    Transplant Proc; 2007 Sep 20; 39(7):2163-6. PubMed ID: 17889125
    [Abstract] [Full Text] [Related]

  • 28. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan 20; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 29. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 20; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 30. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.
    Transplantation; 2001 Nov 27; 72(10):1675-9. PubMed ID: 11726831
    [Abstract] [Full Text] [Related]

  • 31. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.
    Am J Transplant; 2009 Aug 27; 9(8):1876-85. PubMed ID: 19563339
    [Abstract] [Full Text] [Related]

  • 32. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
    Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B, Oyer P, Valantine H.
    Transplantation; 2005 Aug 27; 80(4):477-81. PubMed ID: 16123721
    [Abstract] [Full Text] [Related]

  • 33. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA, Osuna A, Capdevilla L, Cantarell C, Pereira P, Mazuecos A, González Molina M.
    Nefrologia; 2008 Aug 27; 28(3):287-92. PubMed ID: 18590495
    [Abstract] [Full Text] [Related]

  • 34. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group.
    Transplantation; 2005 Apr 15; 79(7):807-14. PubMed ID: 15818323
    [Abstract] [Full Text] [Related]

  • 35. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
    Ciancio G, Burke GW, Suzart K, Mattiazzi A, Vaidya A, Roth D, Kupin W, Rosen A, Johnson N, Miller J.
    Am J Transplant; 2003 Aug 15; 3(8):1010-6. PubMed ID: 12859538
    [Abstract] [Full Text] [Related]

  • 36. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.
    Transpl Int; 2001 Dec 15; 14(6):396-404. PubMed ID: 11793037
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS.
    Liver Transpl; 2005 Sep 15; 11(9):1064-72. PubMed ID: 16123958
    [Abstract] [Full Text] [Related]

  • 38. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients.
    Ciancio G, Burke GW, Suzart K, Mattiazzi A, Rosen A, Zilleruello G, Abitbol C, Montane B, Miller J.
    Transplant Proc; 2002 Aug 15; 34(5):1944-5. PubMed ID: 12176637
    [No Abstract] [Full Text] [Related]

  • 39. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 15; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 40. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun 15; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.